~~<i id='A8262C9157'><strike id='A8262C9157'><tt id='A8262C9157'><pre id='A8262C9157'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

knowledge

author：focus 2025-08-10 11:42:23 - browse：233

A European regulatory panel has recommended against approval of a lung cancer drug made by Mirati Therapeutics, the company said Friday.

Mirati said it will appeal the negative opinion of the drug, called Krazati, issued by a committee of the European Medicines Agency that met this week. But for now, the adverse decision is likely to be adopted by European regulators and prevent the company from marketing the pill in Europe.

Krazati works by blocking a specific type of KRAS alteration called G12C, found in approximately 13% of lung tumors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Readout Newsletter: Parkinson's study, Gilead, CG Oncology

hotspot

leisure time

explore

entertainment

hotspot

focus

FloridaGov.andGOPpresidentialcandidateRonDeSantiswantstoimportCanadianprescriptiondrugs.CharlieNeibe

WSS

What causes osteoarthritis? Researchers study link to brain protein

High breast density mammograms need follow

There's an unseen cost to disruptive road

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Kellogg’s is going to war over Mexico’s nutrition label rules

TikTok, Instagram influencers need more rules for drug ads

focus

knowledge

hotspot

State Dept. review finds Biden bears some blame for Afghanistan failures

Medicare drug price lawsuits could be good politics for Biden

What does generative AI mean for health care? We asked experts

Pumping milk in bathrooms at health conferences is common

Novavax promises a turnaround & Lilly roils the obesity market

Pumping milk in bathrooms at health conferences is common

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Can U.S. cancer drug shortages be fixed?

Medicare details structure of new drug price negotiation program

National associations that represent hospice owe an apology

leisure time

Dog Aging Project founders on what lies ahead after losing funding

Listen: Vivek Ramaswamy's star turn & leaky drug data

CDC says it’s too soon to assess risk posed by Covid subvariant

There's an unseen cost to disruptive road

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

What causes osteoarthritis? Researchers study link to brain protein

explore

entertainment

hotspot

focus